Authors

Latest:

Dr. Olsson on Differences Between LHRH Agonists and Antagonists in Prostate Cancer

Carl Olsson, MD, Integrated Medical Professionals, compares the efficacy of LHRH agonists with antagonists, which are commonly used to treat patients with prostate cancer.

Carla Casulo, MD

Latest:

Dr. Casulo on Predicting Outcomes in Follicular Lymphoma

Carla Casulo, MD, discusses several different factors that can help predict outcomes in patients with follicular lymphoma.

Carla Casulo, MD, University of Rochester Medical Center

Carla Casulo, MD, University of Rochester, Wilmot Cancer Institute

Carlito B. Lebrilla, PhD

Latest:

Glycans Emerge as Promising Biomarkers for Early Detection of Many Cancer Types

For many years, we in the medical and research communities have tried to use proteins and DNA fragments as disease markers to find cancer early.

Carlos Arteaga

Latest:

Dr. Arteaga on PI3K Pathway Inhibitors

Carlos Arteaga, MD, assistant director, Clinical Research, director, Breast Cancer program, Vanderbilt-Ingram Cancer Center, discusses the PI3K pathway and the role of therapeutic inhibitors in reducing the progression of breast cancer.

Carlos Arteaga, MD

Latest:

Dr Arteaga on CDK4/6 Inhibitor Resistance in ER+ Breast Cancer

Carlos Arteaga, MD, discusses the resistance to CDK4/6 inhibitors in estrogen receptor–positive breast cancer.

Carlos Becerra, MD

Latest:

Dr. Becerra Discusses Dosing Strategies in CRC

Carlos Becerra, MD, medical oncologist, Texas Oncology, discusses dosing strategies in the treatment of patients with colorectal cancer.

Carlos E. Vargas, MD

Latest:

Dr. Vargas on Research With Proton Therapy in Prostate Cancer

Carlos E. Vargas, MD, discusses research with proton therapy in prostate cancer.

Carlos H. Barcenas, MD

Latest:

Dr. Barcenas on Colestipol in Management of Neratinib Side Effects in HER2+ Breast Cancer

Carlos Barcenas, MD, assistant professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses managing neratinib-related side effects with colestipol (Colestid).

Carlos H. Barrios, MD, PUCRS School of Medicine

Carlos L. Arteaga, MD

Latest:

Dr. Arteaga Discusses the CALGB 40603 Trial

Carlos L. Arteaga, MD,discusses the CALGB 40603 trial, a neoadjuvant triple-negative breast cancer trial.

Carlos L. Arteaga, MD, Vanderbilt

Carlos L. Arteaga, MD, Vanderbilt University

Carlos R. Bachier, MD

Latest:

Dr. Bachier on the Potential Benefits of Liso-Cel in DLBCL

Carlos R. Bachier, MD, discusses the investigational CAR T-cell therapy lisocabtagene maraleucel in diffuse large B-cell lymphoma.

Carlton Brown, RN, PhD

Latest:

Carlton Brown Describes the ONS Social Media Efforts

Oncology Nursing Society President Carlton Brown Describes the ONS Social Media Efforts

Carlton Brown, RN, PhD, AOCN

Latest:

ONS President Carl Brown on Key Messages of the Congress

Carlton Brown Describes Key Messages of the ONS Congress

Carmelina E. Heydrich, MS, Katherine A. Schneider, MPH

Latest:

When to Consider Referral to a Genetic Counselor for Lesser Known Cancer Syndromes

Experts discuss the clinical features, gene function, and medical management recommendations for six hereditary cancer syndromes.

Carmelo Nucera, MD, PhD

Latest:

Dr. Nucera Discusses the Role of RNA in Thyroid Cancer

Carmelo Nucera, MD, PhD, endocrinologist, assistant professor, Harvard Medical School, Division of Experimental Pathology, Beth Israel Deaconesss Medical Center, Boston, discusses the role of RNA in thyroid cancer

Carol Aghajanian, MD

Latest:

Dr. Aghajanian on Ovarian Cancer Trial Endpoints

Carol Aghajanian, MD, from the Memorial Sloan-Kettering Cancer Center, discusses the difficulties with a gold standard clinical trial endpoint in ovarian cancer.